Clinical Trial Update: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy [Phase 2, Phase 3]

View source ↗

Summary

Biohaven is conducting a Phase 2/3 trial to assess the safety and efficacy of BHV-7000 in adults with refractory focal onset epilepsy. The study is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Epilepsy

Drugs mentioned

• BHV-7000

Snippet

Sponsor: Biohaven Therapeutics Ltd. | Conditions: Focal Epilepsy | Phase 2, Phase 3 | Status: RECRUITING